Research programme: haemophilia gene therapies - Bioverativ/Oxford BioMedica

Drug Profile

Research programme: haemophilia gene therapies - Bioverativ/Oxford BioMedica

Alternative Names: Factor IX - Oxford BioMedica; Factor VIII - Oxford BioMedica

Latest Information Update: 27 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bioverativ
  • Developer Bioverativ; Oxford BioMedica
  • Class Blood coagulation factors; Gene therapies
  • Mechanism of Action Factor IX replacements; Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia A; Haemophilia B

Most Recent Events

  • 27 Mar 2018 Preclinical trials in Haemophilia A in USA (Parenteral) (Oxford BioMedica pipeline, March 2018)
  • 27 Mar 2018 Preclinical trials in Haemophilia B in USA (Parenteral) (Oxford BioMedica pipeline, March 2018)
  • 08 Mar 2018 Bioverativ has been acquired by Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top